Top ten Indian pharmaceutical companies

【Answer 1】 3. Dr. Reddy’s Laboratories Dr. Reddy’s Laboratories is a multinational company headquartered in Hyderabad, Telangana. Established in 1984 as an active pharmaceutical ingredient (API) manufacturer, it ranks third among Indian pharmaceutical companies. As of August 24, 2017, its market capitalization stood at ¥33.65 billion. The company manufactures over 200 pharmaceutical products, supplying them to more than 20 countries worldwide. It specializes in dermatology, cardiology, gastroenterology, and other therapeutic areas. 4. Cipla Founded in 1935 by Dr. Khwaja Abdul Hamied, Cipla is one of India’s largest pharmaceutical companies, currently employing over 20,000 people. As of August 24, 2017, its market capitalization was ¥45 billion. The company operates numerous manufacturing facilities across 34 cities in India. Cipla produces approximately 2,000 products targeting cardiology, neurology, nephrology, and diabetes. 5. Aurobindo Pharma Aurobindo Pharma is a manufacturer of APIs and generic drugs, headquartered in Hyderabad, Telangana. It was founded in 1986 by Dr. N. K. Reddy and Dr. R. P. Reddy. The company primarily focuses on six therapeutic areas: antiallergics, gastroenterology, antiretrovirals, antibiotics, central nervous system disorders, and cardiology. Its market capitalization stands at approximately ¥41.1 billion. 6. Cadila Healthcare Cadila Healthcare, headquartered in Ahmedabad, Gujarat—the westernmost state of India—was established in 1952. It operates manufacturing units in 20 cities nationwide. The company mainly develops medications for cardiology, gastroenterology, neurology, and pulmonology. Cadila Healthcare’s market capitalization is approximately ¥49.6 billion. It produces around 3.5 billion dosage units annually. 7. Glenmark Pharmaceuticals Glenmark Pharmaceuticals is an Indian pharmaceutical company founded in 1977 and headquartered in Mumbai, Maharashtra. It maintains manufacturing facilities across several Indian states, including Maharashtra, Goa, Karnataka, and Gujarat. Glenmark is renowned for developing and marketing APIs and formulated products covering therapeutic areas such as diabetes, dermatology, ear-nose-throat (ENT), internal medicine, gynecology, and pediatrics. As of August 24, 2017, Glenmark’s market capitalization was approximately ¥17.18 billion. 8. GlaxoSmithKline (GSK) GlaxoSmithKline Pharmaceuticals was founded in 1924 and is among the oldest pharmaceutical companies in India—though originally a British firm. GSK leads in vaccine provision, including vaccines against hepatitis A and B, Haemophilus influenzae type b (Hib), varicella, diphtheria, pertussis, tetanus, rotavirus, and cervical cancer. The company’s primary product portfolio includes anti-infectives, dermatologicals, oncology drugs, gynecologicals, antidiabetics, cardiology agents, and respiratory therapeutics. As of August 24, 2017, GSK’s market capitalization was ¥20.15 billion.

[Breaking News] Indian pharmaceutical giant Glenmark Pharmaceuticals secures patent licensing rights for Minoxiboost—the Minoxidil-enhancing coenzyme

【Answer 2】 We warmly congratulate Glenmark Pharmaceuticals, a prominent Indian pharmaceutical company, on securing commercialization rights for Minoxiboost—the Minoxidil-enhancing coenzyme—from Jupiter Wellness. This marks another key partnership following earlier launches in the U.S., China, Japan, and other countries! Notably, the Indian version of Minoxiboost is now officially available for sale in India. Regular followers of Mijiji are already familiar with the Minoxiboost coenzyme serum. The efficacy of minoxidil hinges critically on sulfotransferase enzyme activity—but individual variations in sulfotransferase levels lead to dramatically divergent clinical outcomes: some users experience rapid hair regrowth, while others see no response whatsoever. This variability stems from differences in SULT1A1 enzyme (sulfotransferase) expression. Scientists discovered long ago that suboptimal minoxidil responses stem from insufficient scalp sulfotransferase levels, thereby impairing minoxidil’s hair-regrowth effects. This foundational insight was first clinically investigated by renowned international dermatology professor Andy Goren and his team, who pioneered clinical trials exploring sulfotransferase modulation in alopecia treatment—and subsequently validated effective intervention strategies. In 2014, experts conclusively demonstrated the direct correlation between sulfotransferase enzymatic activity and minoxidil responsiveness through extensive research. In 2015, U.S.-based AB Biotech became the first company to launch MinoxiTest—a diagnostic assay quantifying minoxidil responsiveness via sulfotransferase activity modulation—and obtained FDA clearance. In 2018, the world’s first patented formulation—Minoxibooster—was developed to stimulate hair follicle cells to produce increased levels of sulfotransferase, thereby innovatively resolving the core challenge of enhancing cellular sulfotransferase synthesis. In 2020, Minoxibooster—the coenzyme serum designed to boost sulfotransferase production and thereby enhance minoxidil efficacy—completed development, rigorous testing, and global patent filings.

India's Glenmark quarterly profit falls on lower North America sales

14 hours ago

Glenmark Pharmaceuticals reported a 56.8% drop in Q2 profit due to lower North American sales, despite core business growth. The company also settled a $15.28 million dispute with Humana and saw material costs rise 16%.

reuters

2026-11-05

India's Glenmark quarterly profit falls on lower North America sales

India's Glenmark quarterly profit falls on lower North America sales

FAQ